# scientific reports



# **Assessment of respiratory OPEN mechanics and X‑ray velocimetry functional imaging in two cystic fbrosis rat models**

 $N$ icole <code>Reyne<sup>1,2,3⊠</code>, <code>Ronan</code> <code>Smith<sup>1,2,3</sup>, Patricia Cmielewski<sup>1,2,3</sup>, Nina Eikelis<sup>4</sup>, Mark Lawrence<sup>5</sup>,</code></sup></code> **Jennie Louise6 , Piraveen Pirakalathanan4 , David Parsons1,2,3 & Martin Donnelle[y](http://orcid.org/0000-0002-5320-7756) 1,2,3**

**Two cystic fbrosis (CF) rat models, one carrying the common** *Phe508del* **mutation and the other a nonsense cystic fbrosis transmembrane conductance regulator (CFTR) mutation (knockout) were previously characterised. Although relevant CFTR mRNA reductions were present in the lung, no overt CF lung disease was observed. This study used fexiVent lung mechanic assessment and regional ventilation assessment via X-ray velocimetry (XV) functional imaging to assess the lung phenotype in both models. To determine the sensitivity of XV regional ventilation imaging, the efect of a localised physical obstruction (delivery of agar beads to part of the lungs) on lung ventilation was examined. At baseline,** *Phe508del* **and knockout CF rats had a lower inspiratory capacity, total respiratory system compliance, and static compliance than wildtype rats. Following agar bead delivery all XV ventilation parameters were altered, with substantial increases in poorly ventilated regions and ventilation heterogeneity. XV ventilation maps accurately identifed locations of bead-induced airfow changes. Despite unremarkable lung histopathology, this study indicated that CF rats display altered respiratory mechanics, with CF rats needing to exert additional efort to expand and defate their lungs due to increased stifness. This study demonstrated the utility of XV imaging providing spatial lung ventilation information.**

**Keywords** Cystic fbrosis, Animal models, Lung, Lung function, X-ray velocimetry, fexiVent

Cystic fibrosis (CF) is a life-shortening genetic disease that affects multiple organs<sup>[1](#page-8-0)</sup>, but lung disease causes the majority of morbidity and mortality. The CF transmembrane conductance regulator (*CFTR*) is a chloride and bicarbonate ion transport channel on epithelial surfaces that contributes to the absorption and secretion of ions. Pathogenic variants of the *CFTR* gene result in defective CFTR function and altered chloride ion movement, leading to dehydration of the airway surface liquid and impaired mucociliary clearance<sup>2</sup>. Bacteria entering the lungs adhere to the accumulated mucus and are unable to be cleared, resulting in a persistent cycle of infection and inflammation. The combination of mucus stasis, bacterial infections and inflammation contribute to altered lung architecture and airway remodelling, resulting in an obstructive lung disease and progressive decline in lung function. Lung function tests such as spirometry, body plethysmography and multiple breath washout in those with CF are important tools for monitoring pulmonary exacerbation, disease progression and treatment outcomes<sup>[3](#page-8-2)</sup>. In humans these are often combined with lung imaging via computed tomography (CT), or more recently magnetic resonance imaging, to identify structural lung disease including bronchiectasis, mucus plugging, atelectasis, bronchial wall thickening, air trapping and ventilation inhomogeneity<sup>4</sup>.

Numerous animal models of CF have been developed, with each displaying a varied CF phenotype<sup>[5](#page-8-4),[6](#page-8-5)</sup>. Recently, two CF rat models, one carrying the common *Phe508del* mutation and the other a *CFTR* knockout were gener-ated in Adelaide, South Australia<sup>[7](#page-8-6)</sup>. Both models exhibit reduced survival, intestinal obstructions, defects in the male reproductive tract, and a CF bioelectrical profle in the nasal epithelium. However, the classic overt CF muco-obstructive lung disease and histopathology were not observed in either CF rat model, although reduced

<sup>1</sup>Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia. <sup>2</sup>Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia. <sup>3</sup>Respiratory and Sleep Medicine, Women's and Children's Hospital, Adelaide, SA, Australia. <sup>4</sup>4DMedical, Melbourne, VIC, Australia. <sup>5</sup>SCIREQ Scientific Respiratory Equipment Inc, Montreal, QC, Canada. <sup>6</sup>Biostatistics Unit, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.<sup>⊠</sup>email: nikki.reyne@adelaide.edu.au

CFTR mRNA was present in the lung. McCarron (2020) did not investigate whether lung function diferences were present in either of the CF rat models, and this has not been described elsewhere<sup>[6](#page-8-5)</sup>.

In research animals the gold standard for measuring airway mechanics is currently the fexiVent small animal ventilator<sup>[8](#page-8-7)</sup>. The flexiVent directly measures pulmonary and airway mechanics by performing a series of forced perturbations and measuring the feedback from the lung. Multiple studies have found that CF mice have an increase in airway resistance, tissue damping, and tissue elasticity when compared to wildtype mice, even in the absence of histopathological findings<sup>[9–](#page-8-8)11</sup>. CF pigs also have similar lung function differences at birth with an increased airway resistance<sup>12</sup>. As with clinical spirometry, although the flexiVent can provide information about lung function, including separation between central and peripheral airways, it cannot spatially localise where within the lung those changes in airfow originate.

X-ray velocimetry (XV) is a new lung imaging technology that is able to provide novel information about lung health<sup>[13](#page-8-11),[14](#page-8-12)</sup>. When combined with custom XV analysis software, a Permetium preclinical XV scanner (4DMedical, Melbourne, Australia) is able to track the motion of the lung tissue, and display full dynamics of airfow throughout the lung over a breath cycle[15,](#page-8-13)[16.](#page-8-14) For laboratory animals, XV ventilation data is acquired using a form of time-resolved CT, in which the volume of multiple (~4000) regions of the lung are tracked throughout the breath. For each region, a parameter called specifc ventilation is measured, and is defned as the change in volume of that region relative to the volume of the region at peak exhalation  $(\Delta V/V_0)$ . 3D maps can be used to visualise the specifc ventilation data, in the same way absorption values are displayed in traditional CT data.

XV has been applied in animal studies including the β-ENaC mouse model of CF lung disease, to obtain functional information on dynamic airflow and lung function<sup>17,18</sup>. Those studies demonstrated clear differences in the  $\beta$ -ENaC mouse model compared to wildtype littermates, with patchy ventilation corresponding to mucus plugging detected by high-resolution CT and histology. Werdiger et.al provided a quantitative analysis of thi[s19](#page-8-17). More recently, XV has been used to analyse lobar differences in asthma mouse models<sup>[20](#page-8-18)</sup>. Together these studies suggest XV could be a valuable tool for assessing lung disease in  $CF$  rat models<sup>21</sup>.

The first aim of this study was to use flexiVent and XV measurements to determine if there are differences in lung function between knockout, *Phe508del* and wildtype rats. The second aim consisted of two parts, firstly to determine if the genotypes would respond diferently to an insult from a delivery of agar beads to the lung, and secondly whether XV could detect the location of any airfow defects from this insult.

# **Methods**

#### **Animals**

All animal procedures were approved by the South Australia Health and Medical Research Institute (SAH-MRI) animal ethics committee under application SAM424.19 and were performed in accordance with the ARRIVE guidelines<sup>22</sup>. Male and female knockout (510X), *Phe508del* and wildtype rats were used (n=7/group) (Sprague–Dawley background[\)7](#page-8-6) . Animals were distributed into experimental groups according to genotype, and randomly allocated to receive sterile agar beads (see below) into either their left or right main bronchus. The use of animals of a single sex was not possible due to the challenges associated with breeding large numbers of CF rats. All rats were maintained in conventional cages with a 12-h light/dark cycle. Food and water were provided *ab libitum*, with all rats receiving a 50:50 mix of normal and high fat (10%) rodent chow. CF rats received water containing 4.5% ColonLytely (Dendy Pharmaceuticals, Australia) to minimise CF related gut obstructions. All imaging and lung function tests were performed at the SAHMRI Preclinical Imaging and Research Laboratories (PIRL, South Australia).

# **X‑ray velocimetry (XV)**

Rats were anaesthetised with a mixture of 60–75 mg/kg of ketamine (Ceva, Australia) and 0.4–0.5 mg/kg medetomidine (Ilium, Australia), delivered by intraperitoneal injection. Once anaesthetised, the rats were prepared by performing a tracheostomy and cannulation with a cut-down endotracheal tube (ET; 14 Ga BD Insyte plastic cannula bevel cut to 15 mm length), and then restrained in a custom 3D printed holder in an upright position. XV imaging was performed with a Permetium preclinical scanner (4DMedical, Australia), confgured with a 1700 mm sample to detector distance. For XV scan acquisition, each rat was placed onto the translation/rotation stage of the Permetium. Animals were connected to a small animal ventilator (4DMedical Accuvent 200, Australia) configured to a peak inspiratory pressure of 14 cmH<sub>2</sub>O, positive end-expiratory pressure of 2 cmH<sub>2</sub>O, and ventilated at 93.75 breaths/min (192 ms inspiration and 448 ms expiration; I:E ratio of 3:7). A 4D XV scan was then acquired at a framerate of 15.625 Hz, with 10 images per breath and 600 projections per phase-point. The scan time was  $\sim$  6 min.

In this study, the specifc ventilation was only assessed during the inspiratory phase of the breath. Using these X-ray images, specific ventilation values were calculated at  $\sim$  4000 voxels within the lungs by 4DMedical using their proprietary XV analysis algorithms. From these, the standard parameters of mean specifc ventilation (MSV) and ventilation heterogeneity (VH) were calculated. Normalised ventilation defect percentage (nVDP) was calculated using 60% of the MSV of the wildtype group to defne a fxed threshold. To explore regional variations, these parameters were also calculated on subsets of the lung volume. Further analysis of the lung volume was done using a custom Python script that bisected the lung into left and right halves. A face-on view was found by rotating the lungs (about the head-to-tail axis) until the separation between the two halves was greatest, bisecting where the lungs were thinnest. The whole-lung metrics defined in Table [1](#page-2-0) were used to describe the characteristics of the resulting specifc ventilation histogram.

2



<span id="page-2-0"></span>**Table 1.** X-ray Velocimetry terminology and metrics.

### **fexiVent**

Immediately following XV imaging, lung function assessments were performed using a fexiVent FX small animal ventilator fitted with a FX4 rat module (SCIREQ, Montreal, Canada) with rats in a supine position. The 14 Ga cannula was connected to the fexiVent and ventilatory parameters set at respiratory rate 90 breaths/min, tidal volume 10 mL/kg and positive end expiratory pressure (PEEP) of 3 cmH<sub>2</sub>O. Lung mechanics measurements were made using the SCIREQ automated algorithms confgured in a rat mechanics scan script that was repeated three times.

A Deep Infation manoeuvre maximally infated the lungs to a pressure of 30 cmH2O, held over a period of 3 s, to reset lung volume history and measure the inspiratory capacity (IC). A single-frequency (SnapShot-90) perturbation matching the rat respiratory rate and tidal volume, was used to ft the single-compartment model, enabling calculation of the total respiratory system resistance  $(R_{rs})$ , compliance  $(C_{rs})$ , and elastance  $(E_{rs})$ . A broadband (Quick Prime-3) forced oscillation perturbation was then applied, using a range of frequencies above and below the respiratory rate, to which the flexiWare software fit the constant-phase model of respiratory system impedance ( $Z_{rs}$ ) to calculate Newtonian resistance ( $R_n$ ), tissue damping (G), and tissue elastance (H). The hysteresivity (Eta) was calculated by dividing G by H. Stepwise pressure-controlled pressure–volume (PVs-P) loops were generated and fexiWare automatically ftted the Salazar-Knowles equation to the expiratory data to obtain an inspiratory capacity estimate (A), curvature of the defating PV loop (K), and quasi-static compliance  $(C<sub>st</sub>)$ . The PV loop area (hysteresis) was also calculated. Data was excluded from any model if the model fit was poor (coefficient of determination less than 0.9). For each parameter, an average of the three measurements was calculated per rat. IC was normalised to body weight.

#### **Sterile agar beads**

Sterile agar beads were prepared using previously established methods<sup>[23](#page-8-21),[24](#page-8-22)</sup>, in which 2% molten agar was added to rapidly spinning warmed mineral oil (53 °C) and cooled for 10 min. Agar beads were washed once with 0.5% deoxycholic acid (DCA), once with 0.25% DCA, and three times with phosphate bufered saline, then centrifuged at 1800 RPM for 10 min, with the top layer of oil removed each time. The agar beads (50–100 μm diameter) were resuspended in an equal volume of phosphate bufered saline to form a bead slurry.

Following baseline XV and fexiVent measurements, 50 μl of agar beads were delivered to either the lef or right main bronchus by miniature brochscope<sup>25</sup>, with rats randomly assigned to each group (either left or right side delivery). Post-bead XV scan and fexiVent measurements were then performed. Afer all analyses animals were humanely killed by overdose of 150 mg/kg sodium pentobarbital (Lethabarb, Virbac, Australia).

#### **Histology**

Lungs were fxed in 10% phosphate-bufered formalin, embedded in parafn and sectioned at 5 μm. Sections were stained with Haematoxylin and Eosin. Images were examined and captured on a Nikon Eclipse E400 microscope (Tokyo, Japan) with DS-Fi2-U3 camera and Nikon NIS-elements D sofware version 5.42.08 (Tokyo, Japan).

# **Statistics**

Statistical analyses were performed in R version  $4.3.1^{26}$ . ANOVA was used to measure whether age or weight difered substantially at baseline. To assess diferences in the fexiVent and XV parameters at baseline between genotypes, and the change from pre- to post-bead delivery within each genotype, a linear mixed efects model was fitted to each parameter using the *lmer* function from the *lme4* package<sup>27</sup>. This model contained fixed effects of genotype, weight, time point, an interaction between genotype and time point, plus a random efect of animal ID. Sex was not included as a variable in the model due to model overftting. A second model was ftted to assess diferences between group parameters afer bead delivery, and the potential for efect modifcation due to the (half) lung into which the beads were delivered. Tis model contained fxed efects of the baseline parameter value, genotype, the treated lung (left or right), and an interaction between genotype and the treated lung. Pairwise comparisons for each fitted model were performed using the *emmeans* package<sup>28</sup>. Results are presented graphically as estimated marginal means and 95% confdence intervals. Supplementary Table 1 shows the diferences in estimated marginal mean between the genotypes and 95% confdence intervals for each parameter, as well as the actual *p* value. Supplementary Table 2 shows the diference in the estimated marginal mean between baseline and post-beads, 95% confdence intervals and the actual *p* value.

# **Results**

#### **Animals**

Table [2](#page-3-0) shows the characteristics of the three groups. The age distribution was similar between the groups of rats, however the *Phe508del* and knockout rats weighed less on average than the wildtype rats.

#### **Baseline comparison between genotypes**

When normalised to body weight, the Deep Infation manoeuvre showed that wildtype rats had a higher inspira-tory capacity IC<sub>norm</sub> compared to CF rats (Fig. [1](#page-3-1)A, supplementary Table 1). A single frequency forced oscillation (SnapShot-90) demonstrated total respiratory system compliance  $C_{rs}$  was lower in knockout rats compared to wildtype (Fig. [1](#page-3-1)B). Total respiratory system resistance  $R_{rs}$  was not notably different in either CF rat model compared to wildtype (Fig. [1](#page-3-1)C).

The broadband forced oscillation technique (Quick-Prime 3), which measured Newtonian resistance, tissue damping, elastance, and hysteresivity, showed that there was no substantial diference between wildtype and CF rats at baseline (Supplementary Table 1).

Average pressure volume loops (PVs-P) constructed from mean data showed a downward shif in the *Phe508del* and knockout rats compared to wildtype rats (Fig. [2\)](#page-4-0). The static compliance C<sub>sp</sub>, signifying the intrinsic elastic properties of the lung and chest wall, was lower in *Phe508del* and knockout rats compared to wildtype rats (Fig. [2](#page-4-0)).

There were no notable differences between the genotypes in any of the XV parameters at baseline (Supplementary Table 1).

#### **Comparison after bead delivery**

Figure [3](#page-4-1) shows an example of a sterile agar bead obstructing a small airway in the right lower lobe following a bronchoscopic delivery to the right main bronchus.

Post-bead delivery there was a decrease in respiratory system compliance  $C_{rs}$  in the wildtype rats compared to baseline. Post-beads there were increases in the tissue damping and tissue hysteresivity in *Phe508del* rats. All



<span id="page-3-0"></span>Table 2. Rat characteristics. Values are presented as mean ± SD, and differences analysed by ANOVA with post-hoc comparisons to wildtype.



<span id="page-3-1"></span>**Fig. 1.** Respiratory system mechanics in wildtype, *Phe508del* and knockout rats. (**A**) Normalised inspiratory capacity, (**B**) total respiratory system compliance and (**C**) resistance (n=7 animals/genotype, linear mixed efect model, estimated marginal means and 95% CIs).

4



<span id="page-4-0"></span>**Fig. 2.** Pressure–volume loops in wildtype, *Phe508del* and knockout rats. Baseline pressure volume loops were generated using a volume-controlled stepwise manoeuvre (PVs-V) for each genotype. **(A)** Raw pressure volume loops, and **(B)** static compliance (n=7 animals/genotype, linear mixed effects model, estimated marginal means and 95% CIs).



<span id="page-4-1"></span>**Fig. 3.** Representative haematoxylin and eosin image of a sterile agar bead within an airway in the right lower lobe of a rat lung. Scale bar 100 μm.

genotypes had a reduction in the parameter K of Salazar-Knowles equation post-bead delivery, and the PV loop hysteresis was increased in the *Phe508del* and wildtype rats post-beads (supplementary Table 2).

Following delivery of agar beads XV analysis revealed that the MSV was decreased in all genotypes. Normalised VDP and VH were increased in *Phe508del,* and wildtype rats post-bead delivery compared to baseline (Fig. [4](#page-5-0)).

Examples of ventilation maps at baseline and afer agar bead delivery to the lungs are shown in Fig. [5.](#page-5-1) Differences between the left and right lung were obvious for all animals, with those having right side bead delivery showing reduced ventilation (red) on the corresponding right side, while the lef side had areas of higher ventilation (blue). With the exception of MSV, there was no evidence that any of the measures were afected by the choice of lung that received the beads. That is, the differences between genotypes were not affected by whether the right or left lung received the beads.

To quantify regional diferences in ventilation, the specifc ventilation data for each lung was determined by splitting the whole lung volume into left and right components for analysis. MSV was then calculated in each side of the lung, for the baseline and for the post-bead delivery datasets. The example histograms from two rats



<span id="page-5-0"></span>**Fig. 4.** X-ray Velocimetry parameters at baseline and post-bead delivery in wildtype, *Phe508del* and knockout rats. (**A**) Mean specifc ventilation, (**B**) normalised ventilation defect percentage, and **(C)** ventilation heterogeneity. (n = 7 animals/genotype, linear mixed effect model, estimated marginal means and 95% CIs).



<span id="page-5-1"></span>**Fig. 5.** Visualisation of changes in local ventilation, and frequency distribution of specifc ventilation, afer agar bead delivery to the lung. (A) The top row shows a rat that received agar beads to the right lung, and (B) the bottom row shows a rat that received an agar bead delivery to the left lung. Left panel (pre-beads) and middle panel (post-beads): A single mid-coronal slice and three axial slices (upper, middle and lower), showing normalised specifc ventilation at peak inspiration. Green indicates average ventilation, red below average ventilation, and blue above average ventilation. Red circle indicates the side beads were delivered to. Right panel: Average histograms of mean specifc ventilation in right (blue) and lef (red) lungs pre- (solid line) and postbead (dot line) delivery in rats.

shown in Fig. [5](#page-5-1) (right panel), indicate that the lef and right lung had a similar specifc ventilation distribution prior to delivery. However, once the beads were delivered, the MSV decreased in the lung that received beads.

Figure [6](#page-6-0) shows how the MSV value of each lung in every animal changed after the beads were delivered. The background of the plot is coloured, with the light-red zone showing animals in which the MSV was decreased in both lungs, the yellow zone where one lung had decreased MSV and the other had an increased MSV (i.e. the lung displays compensation), and the green zone where both lungs had an increased MSV. The intersection point indicates the point of no MSV change; the rat at this point exhibits what we consider to be a normal untreatedanimal ventilation map, showing mostly green level ventilation, with some red (low ventilation) around the heart. Most rats reside in the yellow zone, indicating that the MSV decreased in one lung, and increased in the other. The rats that had ventilation changes in the light-red and green zones were all close to the intersection point,



<span id="page-6-0"></span>**Fig. 6.** Localised changes in ventilation can be visualised and quantifed. A single mid-coronal slice from diferent rats showing diferent areas of ventilation depending on where the bead delivery occurred. Red zones indicate below average ventilation, blue above average ventilation, and green average ventilation. Each rat is marked with the letter L or R to indicate which lung received the bead dose and is coloured by genotype. These

fve rats were selected to show the diferent maps that result from animals in diferent locations on the plane.

7

indicating that their specific ventilation changes were comparatively small. The group of animals circled show how the changes in right-side MSV could vary, while the changes in lef-side MSV remained relatively constant.

#### **Discussion**

In human CF lung disease, a signifcant clinical feature is the progressive decline in lung function. Pulmonary function tests serve as essential tools for tracking lung disease progression in CF, as well as describing the respiratory system characteristics. Animal models of CF are invaluable for investigating disease pathogenesis and conducting treatment development studies. While several animal models of CF have been developed, many of them do not replicate the lung phenotype observed in people with CF<sup>[5](#page-8-4)</sup>. The present study extends our original characterisation of two CF rat models, and we demonstrate for the frst time that CF rats have altered respira-tory mechanics, even in the absence of histopathological evidence of lung disease<sup>[7](#page-8-6)</sup>. In that characterisation, the *Phe508del* rat typically had an intermediate phenotype for the parameters we reported. In the present study, the *Phe508del* rat also exhibited an intermediate lung phenotype compared to the knockout and wildtype rats<sup>7</sup>.

The flexiVent assessments identified differences in the lung function of CF rats at baseline. We chose to age-match rather than weight-match the rats in our study design. Weight matching would have necessitated the use of younger wildtype rats, potentially introducing additional variables due to the immaturity of their respiratory system. By not weight-matching, we ensured that the CF rats were comparable to wildtypes in their age-appropriate characteristics, allowing us to evaluate the impact of the CF genotype on lung function, and as a result the CF rats were smaller than the wildtype rats.

Single frequency forced-oscillation assessment (Single Compartment Model) provides a comprehensive evaluation of the resistive and elastic properties of the respiratory system, encompassing the lungs, chest wall and airways. At baseline, knockout CF rats exhibit lower dynamic compliance compared to wildtype rats, suggesting that CF rats have stifer lungs. Pressure-driven pressure volume loops were used to further assess the compliance of the respiratory system across the entire inspiratory capacity. When performed at baseline, CF rats also exhibited reduced static compliance, indicating a respiratory system (comprising the lung and chest wall) that is less distensible. This observation aligns with the outcomes obtained from the forced-oscillation analysis.

Comparable lung function outcomes were observed using the fexiVent system in two separate studies involv-ing CF mice<sup>9</sup> and a mouse model of fibrosis<sup>[29](#page-8-27)</sup>. In the study conducted by Darrah (2016), two different CF mouse models were characterised against their littermate wildtype[s9](#page-8-8) . Signifcant changes in resistance between central and peripheral airways were reported, with the peripheral airways being the primary source of increased resist-ance in CF mice due to the decreased static compliance<sup>[9](#page-8-8)</sup>. Furthermore, this model confirmed an enlargement of the distal airspaces as the anatomical basis for changes in pulmonary mechanics. Tese studies collectively highlight the efectiveness of the fexiVent system as a valuable tool for assessing lung function in rodent models. Nevertheless, the parameterized lung mechanics of the fexiVent do not allow for spatial mapping of changes that may be these localised alterations in airfow, especially where unafected lung areas compensate for the affected regions<sup>[8](#page-8-7)</sup>.

The second aim was to investigate the impact of a single-lung insult on the lung parameters measured by the fexiVent and XV systems, and in particular if these obstructive efects could be localised to the locations where beads were delivered. The agar beads were delivered to either the right or left main bronchus after the baseline measurements were performed. The pressure volume loop parameters were altered, with changes in the area and shape of the curve observed. However, the fexiVent is unable to spatially determine the location within the lung where the agar beads were delivered.

XV ventilation analysis provided a wealth of information about the lung post bead delivery. All XV parameters in the wildtype and *Phe508del* rats were altered post-bead delivery. Interestingly, the knockout rats unexpectedly observed no diference post-bead delivery. Most importantly, changes in ventilation post-bead delivery clearly could be visualised in the ventilation maps. While this study only presented 2D representations of XV data, it is important to note that XV data can be visualised in 4D format (3D plus time), which could provide even more detailed insights to ventilation.

To delve deeper into the changes of the ventilation, the raw data from specifc ventilation across the lung was divided into left and right lung components. We then compared the pre- and post-bead delivery histograms of the right and lef lungs, revealing changes in ventilation on both sides that were consistent with how targeted bead obstructions would be predicted to affect lung ventilation. These changes were quantified and visualised and showed that the specifc ventilation of each rat was afected diferently by the same delivery of beads to the lung. Future studies should examine whether this type of approach can be used to quantify obstruction severity.

Lung function measurements play a crucial role in diagnosing, monitoring, and assessing outcomes in CF. The current gold standard in human lung function assessment is spirometry, which measures dynamic volumes and capacities during forced expiration and inspiration. It provides essential data such as forced expiratory volume in one second (FEV<sub>1</sub>) and forced vital capacity (FVC) in older children and adults. However, spirometry has its limitations. As a global measure, it may lack sensitivity in detecting small changes and might not always ofer valuable diagnostics information, or target treatments. In CF, the lung disease can be heterogeneous, and these measurements are unable to capture detail of within-lung variability. Additionally, spirometry requires efortdependent cooperation, making it unsuitable for children under the age of six. Recent studies have validated the use of XV in a cohort of non-lung cancer patients<sup>[30](#page-8-28)</sup>, and healthy volunteers<sup>31</sup>, and was shown to produce repeatable and quantitative regional ventilation data. The next key step is to assess XV utility as a monitoring tool in paediatric CF patients<sup>32</sup>. This could transform CF care by offering a more detailed, less effort-dependent method for monitoring lung function and tailoring treatments.

In conclusion, the present study is the frst to demonstrate lung function diferences in CF rat models, using the fexiVent and XV imaging. Further, in determining the efect of an obstruction on the lung, XV also provided information about the location efect of those airway obstructions.

#### **Data availability**

The data can be found at<https://doi.org/10.25909/25734549>.

Received: 6 June 2024; Accepted: 28 August 2024 Published online: 17 September 2024

#### **References**

- <span id="page-8-0"></span>1. Vallières, E. & Elborn, J. S. Cystic fbrosis gene mutations: Evaluation and assessment of disease severity. *Adv. Genomics Genet.* **4**, 161 (2014).
- <span id="page-8-1"></span>2. Malhotra, S., Hayes, D. Jr. & Wozniak, D. J. Cystic fbrosis and pseudomonas aeruginosa: Te host-microbe interface. *Clin. Microbiol. Rev.* **32**(3), 10–128 (2019).
- <span id="page-8-2"></span>3. Kołodziej, M. *et al.* Lung function imaging methods in cystic fbrosis pulmonary disease. *Respir. Res.* **18**, 1–11 (2017).
- <span id="page-8-3"></span>4. Ramsey, K. A. *et al.* Lung clearance index and structural lung disease on computed tomography in early cystic fbrosis. *Am. J. Respir. Crit. Care Med.* **193**(1), 60–67 (2016).
- <span id="page-8-4"></span>5. McCarron, A., Donnelley, M. & Parsons, D. Airway disease phenotypes in animal models of cystic fbrosis. *Respir. Res.* **19**(1), 54 (2018).
- <span id="page-8-5"></span>6. McCarron, A., Parsons, D. & Donnelley, M. Animal and cell culture models for cystic fbrosis: Which model is right for your application?. *Am. J. Pathol.* **191**, 228–242 (2020).
- <span id="page-8-6"></span>7. McCarron, A. *et al.* Phenotypic characterization and comparison of cystic fbrosis Rat models generated using CRISPR/Cas9 gene editing. *Am. J. Pathol.* **190**(5), 977–993 (2020).
- <span id="page-8-7"></span>8. Ahookhosh, K., Vanoirbeek, J. & Vande Velde, G. Lung function measurements in preclinical research: What has been done and where is it headed?. *Front. Physiol.* **14**, 1130096 (2023).
- <span id="page-8-8"></span>9. Darrah, R. J. *et al.* Early pulmonary disease manifestations in cystic fbrosis mice. *J. Cyst. Fibros.* **15**(6), 736–744 (2016).
- 10. Craig Cohen, J. et al. The "Goldilocks Effect" in Cystic Fibrosis: Identification of a lung phenotype in the cftr knockout and heterozygous mouse. *BMC Genet.* **5**(1), 21 (2004).
- <span id="page-8-9"></span>11. Haque, A. *et al.* Chemically modifed hCFTR mRNAs recuperate lung function in a mouse model of cystic fbrosis. *Sci. Rep.* **8**(1), 1–14 (2018).
- <span id="page-8-10"></span>12. Adam, R. J. *et al.* Air trapping and airfow obstruction in newborn cystic fbrosis piglets. *Am. J. Respir. Crit. Care Med.* **188**(12), 1434–1441 (2013).
- <span id="page-8-11"></span>13. Vliegenthart, R. *et al.* Innovations in thoracic imaging: CT, radiomics, AI and x-ray velocimetry. *Respirology* **27**(10), 818–833 (2022).
- <span id="page-8-12"></span>14. Parsons, D. & Donnelley, M. Will airway gene therapy for cystic fbrosis improve lung function? New imaging technologies can help us find out. *Hum.* Gene Ther. **31**(17–18), 973–984 (2020).
- <span id="page-8-13"></span>15. Dubsky, S. *et al.* Synchrotron-based dynamic computed tomography of tissue motion for regional lung function measurement. *J. R. Soc. Interface* **9**(74), 2213–2224 (2012).
- <span id="page-8-14"></span>16. Fouras, A. *et al.* Altered lung motion is a sensitive indicator of regional lung disease. *Ann. Biomed. Eng.* **40**(5), 1160–1169 (2012).
- <span id="page-8-15"></span>17. Murrie, R. P. *et al.* Real-time in vivo imaging of regional lung function in a mouse model of cystic fbrosis on a laboratory X-ray source. *Sci. Rep.* **10**(1), 1–8 (2020).
- <span id="page-8-16"></span>18. Stahr, C. S. *et al.* Quantifcation of heterogeneity in lung disease with image-based pulmonary function testing. *Sci. Rep.* **6**(1), 29438 (2016).
- <span id="page-8-17"></span>19. Werdiger, F. *et al.* Quantifcation of muco-obstructive lung disease variability in mice via laboratory X-ray velocimetry. *Sci. Rep.* **10**(1), 1–12 (2020).
- <span id="page-8-18"></span>20. Asosingh, K. *et al.* Preclinical four-dimensional functional lung imaging and quantifcation of regional airfow: A new standard in lung function evaluation in murine models. *Am. J. Respir. Cell Mol. Biol.* **67**(4), 423–429 (2022).
- <span id="page-8-19"></span>21. Reyne, N. *et al.* Efect of elexacafor-tezacafor-ivacafor on nasal potential diference and lung function in Phe508del rats. *Front. Pharmacol.* **15**, 1362325 (2024).
- <span id="page-8-20"></span>22. Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research<sup>\*</sup>. *J. Cereb. Blood Flow Metab.* **40**(9), 1769–1777 (2020).
- <span id="page-8-21"></span>23. Henderson, A. G., et al., Static mucus impairs bacterial clearance and allows chronic infection with Pseudomonas aeruginosa in the cystic fbrosis rat*.* Eur. Respir. J. (2022).
- <span id="page-8-22"></span>24. van Heeckeren, A. M. & Schluchter, M. Murine models of chronic Pseudomonas aeruginosa lung infection. *Lab. Anim.* **36**(3), 291–312 (2002).
- <span id="page-8-23"></span>25. McIntyre, C. *et al.* Lobe-specifc gene vector delivery to rat lungs using a miniature bronchoscope. *Hum. Gene Ter. Methods* **29**(5), 228–235 (2018).
- <span id="page-8-24"></span>26. R Core Team, *R: A Language and Environment for Statistical Computing*. 2022, R Foundation for Statistical Computing.
- <span id="page-8-25"></span>27. Bates, D. *et al.* Fitting linear mixed-efects models using lme4. *J. Stat. Sofw.* **67**(1), 1–48 (2015).
- <span id="page-8-26"></span>28. Lenth, R.V., *emmeans: Estimated Marginal Means, aka Least-Squares Means*. 2022.
- <span id="page-8-27"></span>29. Devos, F. C. *et al.* Forced expiration measurements in mouse models of obstructive and restrictive lung diseases. *Respir. Res.* **18**(1), 123 (2017).
- <span id="page-8-28"></span>30. Kirkness, J. P. *et al.* Association of x-ray velocimetry (XV) ventilation analysis compared to spirometry. *Front. Med. Technol.* **5**, 1148310 (2023).
- <span id="page-8-29"></span>31. Siddharthan, T. *et al.* Quantifying ventilation by X-ray velocimetry in healthy adults. *Respir. Res.* **24**(1), 215 (2023).
- <span id="page-8-30"></span>32. Matthew, B. *et al.* Pilot study of paediatric regional lung function assessment via X-ray velocimetry (XV) imaging in children with normal lungs and in children with cystic fbrosis. *BMJ Open* **14**(2), e080034 (2024).

#### **Acknowledgements**

The authors acknowledge the facilities and scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the Large Animal Research and Imaging Facility, South Australian Health and Medical Research Institute. The authors acknowledge Wick Lakshantha and Ryan O'Hare Doig for operating the Permetium small animal scanner. Tis project built on experiments M11727, M12061 and M12926 performed on the Imaging and Medical Beamline at the Australian Synchrotron, and the authors thank Kaye Morgan, Marcus Kitchen, and Bernadette Boog for their input.

# **Author contributions**

N.R.: Conceptualisation, Data Curation, Formal analysis, Investigation, Methodology, Visualization, Writing— Original Draf. R.S.: Data Curation, Formal analysis, Investigation, Sofware, Visualization, Writing—Original Draf. P.C.: Investigation, Methodology, Data curation, Writing—Review and Editing. J.L., M.L., N.E., P.P.: Formal analysis, Writing – Review & Editing. D.P.: Conceptualisation, Formal analysis, Resources, Methodology, Supervision, Writing—Original Draf, Writing—Review and Editing. M.D.: Conceptualisation, Data Curation, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Visualization, Writing—Original Draf.

# **Funding**

Studies were supported by NHMRC Project Grant GNT1160011, Cystic Fibrosis Foundation Grant DON-NEL21GO, and the Medical Research Future Fund Grant RFRHPSI000013.

# **Competing interests**

MD and DP were involved in the research development and validation of the XV technology and have personally purchased shares in 4DMedical. NE and PP are employed by 4DMedical. ML is employed by SCIREQ Scientifc Respiratory Equipment Inc.

#### **Additional information**

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/](https://doi.org/10.1038/s41598-024-71632-8) [10.1038/s41598-024-71632-8](https://doi.org/10.1038/s41598-024-71632-8).

**Correspondence** and requests for materials should be addressed to N.R.

**Reprints and permissions information** is available at [www.nature.com/reprints.](www.nature.com/reprints)

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

**Open Access** Tis article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modifed the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/](http://creativecommons.org/licenses/by-nc-nd/4.0/) [licenses/by-nc-nd/4.0/.](http://creativecommons.org/licenses/by-nc-nd/4.0/)

© The Author(s) 2024